Newbury Pharmaceuticals (Sweden) Performance
| NEWBRY Stock | 3.36 0.04 1.20% |
The company secures a Beta (Market Risk) of -0.75, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Newbury Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Newbury Pharmaceuticals is likely to outperform the market. At this point, Newbury Pharmaceuticals has a negative expected return of -0.0159%. Please make sure to verify Newbury Pharmaceuticals' treynor ratio and rate of daily change , to decide if Newbury Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Newbury Pharmaceuticals AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Newbury Pharmaceuticals is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Newbury |
Newbury Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 344.00 in Newbury Pharmaceuticals AB on November 27, 2024 and sell it today you would lose (8.00) from holding Newbury Pharmaceuticals AB or give up 2.33% of portfolio value over 90 days. Newbury Pharmaceuticals AB is generating negative expected returns and assumes 2.2819% volatility on return distribution over the 90 days horizon. Simply put, 20% of stocks are less volatile than Newbury, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Newbury Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Newbury Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Newbury Pharmaceuticals AB, and traders can use it to determine the average amount a Newbury Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.007
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NEWBRY |
Estimated Market Risk
| 2.28 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Newbury Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Newbury Pharmaceuticals by adding Newbury Pharmaceuticals to a well-diversified portfolio.
Newbury Pharmaceuticals Fundamentals Growth
Newbury Stock prices reflect investors' perceptions of the future prospects and financial health of Newbury Pharmaceuticals, and Newbury Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Newbury Stock performance.
| Return On Equity | -0.34 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.89) % | |||
| Operating Margin | (2.75) % | |||
| Current Valuation | 96.57 M | |||
| Shares Outstanding | 19.52 M | |||
| Price To Book | 1.86 X | |||
| Price To Sales | 25.09 X | |||
| Revenue | 5.77 M | |||
| EBITDA | (15.74 M) | |||
| Book Value Per Share | 3.24 X | |||
| Total Asset | 86.91 M | |||
About Newbury Pharmaceuticals Performance
By analyzing Newbury Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Newbury Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Newbury Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Newbury Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Newbury Pharmaceuticals performance evaluation
Checking the ongoing alerts about Newbury Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Newbury Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Newbury Pharmaceuticals generated a negative expected return over the last 90 days | |
| Newbury Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| About 79.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Newbury Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Newbury Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Newbury Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Newbury Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Newbury Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Newbury Pharmaceuticals' stock. These opinions can provide insight into Newbury Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Newbury Stock analysis
When running Newbury Pharmaceuticals' price analysis, check to measure Newbury Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newbury Pharmaceuticals is operating at the current time. Most of Newbury Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newbury Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newbury Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newbury Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |